Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501160 | 0.76 | ALDH1A1 (0.41) | ALDH1A1HSD17B10HPGDCYP1A2CYP3A4 | |
| SCHEMBL18010762 | 0.75 | PLD1 (0.50) | PLD1CRBNMAPK1GAAALDH1A1 | |
| SCHEMBL6497291 | 0.74 | KDM4E (0.35) | KDM4E | |
| SCHEMBL1140766 | 0.74 | PLD1 (0.47) | PLD1CRBNMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL30477095 | 0.74 | CRBN (0.46) | PLD1CRBNMAPK1GAAALDH1A1 | |
| SCHEMBL28004054 | 0.74 | PLD1 (0.38) | PLD1CRBNMAPK1GAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL3827230 | 0.72 | PLD1 (0.46) | PLD1CRBNMAPK1ALDH1A1HSD17B10 | |
| Bromide SCHEMBL6883560 | 0.71 | PLD1 (0.44) | PLD1CRBNMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL5224464 | 0.71 | PLD1 (0.49) | PLD1MAPK1ALDH1A1HSD17B10HPGD | |
| SCHEMBL27508033 | 0.68 | PLD1 (0.46) | PLD1CRBNMAPK1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120226041-A1 | CATALYSTS AND BORONATE ESTERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-09-06 | — | — | US | claimed |
| US-20120226041-A1 | CATALYSTS AND BORONATE ESTERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-09-06 | — | — | US | disclosed |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
| CN-1351646-A | Composition and method for bleaching a substrate | UNILEVER PLC (NL) | 2002-05-29 | — | — | CN | disclosed |
| US-6100404-A | Erythromycin compounds | HOECHST MARION ROUSSEL (FR) | 2000-08-08 | — | — | US | disclosed |
| EP-0680967-B1 | Erythromycin derivatives, their process of preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 1998-10-14 | — | — | EP | disclosed |
| US-5635485-A | Erythromycin compounds | ROUSSEL UCLAF (FR) | 1997-06-03 | — | — | US | disclosed |
| WO-1995029929-A1 | NOVEL ERYTHROMYCIN DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS DRUGS | ROUSSEL UCLAF (FR) | 1995-11-09 | — | — | WO | disclosed |
| EP-0680967-A1 | Erythromycin derivatives, their process of preparation and their use as medicaments | ROUSSEL-UCLAF (FR) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226041-A1 | CATALYSTS AND BORONATE ESTERS | BCHE, BRI3BP, BRAP | PLD1 2421/4885CRBN 940/4885MAPK1 3045/4885 |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | PLD1 3341/4885CRBN 2249/4885MAPK1 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.